Crinetics Pharmaceuticals, Inc.
NASDAQ: CRNX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- R. Scott Struthers
- Employees
- 437
- Headquarters
- San Diego, United States
- IPO year
- 2018
- Market cap
- $3.8B
- Website
- https://www.crinetics.com
Loading CRNX…
Loading profile data…Frequently asked questions about CRNX
What does Crinetics Pharmaceuticals, Inc. (CRNX) do?
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin r...
Where does CRNX trade?
Crinetics Pharmaceuticals, Inc. (CRNX) trades on the NASDAQ Global Select.
What sector is CRNX in?
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Crinetics Pharmaceuticals, Inc.?
R. Scott Struthers is the chief executive officer of Crinetics Pharmaceuticals, Inc. (CRNX).
Where is Crinetics Pharmaceuticals, Inc. headquartered?
Crinetics Pharmaceuticals, Inc. is headquartered in United States.
Does CRNX pay a dividend?
Crinetics Pharmaceuticals, Inc. (CRNX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRNX go public?
Crinetics Pharmaceuticals, Inc. (CRNX) completed its initial public offering in 2018.